Abstract
Pharmacokinetics and bioavailability of famotidine, a new H2-receptor antagonist, were investigated in healthy subjects in five clinical studies. Linear pharmacokinetics were observed following either intravenous or oral administration. Plasma clearance averaged 463 ml min-1. Renal clearance averaged 310 ml min-1, which exceeded the glomerular filtration rate. Renal excretion was the major route of elimination. Urinary recovery of unchanged drug following intravenous administration was about 67 per cent. Famotidine plasma half-life was approximately 2.6 h. Oral absorption was incomplete. The bioavailability averaged 43 per cent of the dose.
Publication types
-
Clinical Trial
-
Controlled Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Administration, Oral
-
Biological Availability
-
Chromatography, High Pressure Liquid
-
Double-Blind Method
-
Drug Evaluation
-
Famotidine
-
Female
-
Gastric Juice / metabolism
-
Histamine H2 Antagonists / administration & dosage
-
Histamine H2 Antagonists / pharmacokinetics*
-
Histamine H2 Antagonists / pharmacology
-
Humans
-
Injections, Intravenous
-
Male
-
Protein Binding
-
Random Allocation
-
Suspensions
-
Tablets
-
Thiazoles / administration & dosage
-
Thiazoles / pharmacokinetics*
-
Thiazoles / pharmacology
Substances
-
Histamine H2 Antagonists
-
Suspensions
-
Tablets
-
Thiazoles
-
Famotidine